|
Daré Bioscience, Inc. (DARE): Business Model Canvas [Jan-2025 Updated]
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Daré Bioscience, Inc. (DARE) Bundle
Daré Bioscience, Inc. (DARE) emerges as a pioneering force in women's healthcare, strategically navigating the complex pharmaceutical landscape through an innovative business model that transforms unmet medical needs into groundbreaking solutions. By leveraging specialized expertise in women's reproductive health, the company crafts a unique value proposition that combines advanced drug delivery technologies with targeted therapeutic approaches, positioning itself as a disruptive player in a traditionally underserved market segment. Their comprehensive Business Model Canvas reveals a meticulously designed strategy that interweaves scientific innovation, strategic partnerships, and patient-centric development to revolutionize women's healthcare solutions.
Daré Bioscience, Inc. (DARE) - Business Model: Key Partnerships
Strategic Collaboration with Pharmaceutical Companies
As of 2024, Daré Bioscience has established key partnerships with the following pharmaceutical companies:
| Partner Company | Collaboration Focus | Partnership Status |
|---|---|---|
| Bayer AG | Women's reproductive health products | Active partnership |
| Organon & Co. | Product development and licensing | Ongoing collaboration |
Licensing Agreements with Academic Research Institutions
Daré Bioscience maintains research collaborations with academic institutions:
- University of California San Diego
- Stanford University School of Medicine
- Johns Hopkins University
Contract Manufacturers
Current contract manufacturing partnerships include:
| Manufacturer | Manufacturing Capability | Contract Value |
|---|---|---|
| Patheon Pharmaceuticals | Oral and injectable product manufacturing | $3.2 million annual contract |
| Catalent Pharma Solutions | Specialized drug delivery systems | $2.7 million annual contract |
Clinical Research Organizations
Active clinical research partnerships:
- ICON plc - Global clinical trial management
- Medpace, Inc. - Phase II and III clinical trials
- IQVIA Holdings Inc. - Regulatory clinical research support
Regulatory Consultants
FDA approval process partnerships:
| Consulting Firm | Regulatory Services | Engagement Type |
|---|---|---|
| Regulatory Compliance Associates | FDA submission preparation | Ongoing consulting |
| Halloran Consulting Group | Regulatory strategy development | Project-based engagement |
Daré Bioscience, Inc. (DARE) - Business Model: Key Activities
Women's Health Product Research and Development
As of Q4 2023, Daré Bioscience focused on developing innovative women's health products with an active R&D pipeline of 4 primary product candidates.
| Product | Development Stage | Therapeutic Area |
|---|---|---|
| Ovaprene | Phase 3 Clinical Trials | Contraception |
| Sildenafil Cream | Phase 2 Clinical Trials | Female Sexual Health |
| Vaginal Hormone Treatment | Pre-clinical Stage | Menopause Management |
Clinical Trial Management
In 2023, Daré Bioscience invested $8.3 million in clinical development activities.
- Active clinical trials across multiple women's health indications
- Collaboration with 3 contract research organizations (CROs)
- Ongoing patient recruitment for Ovaprene Phase 3 study
Regulatory Compliance and Submission
Regulatory engagement costs in 2023 totaled approximately $2.5 million.
| Regulatory Agency | Active Submissions | Status |
|---|---|---|
| FDA | 2 Investigational New Drug (IND) Applications | Under Review |
Product Commercialization Strategies
Marketing and commercialization budget for 2024 projected at $5.7 million.
- Target market: Women's healthcare providers
- Direct sales force of 12 representatives
- Digital marketing budget: $750,000
Intellectual Property Management
IP portfolio investment in 2023 was $1.2 million.
| IP Type | Number of Patents | Geographic Coverage |
|---|---|---|
| Granted Patents | 7 | United States, Europe |
| Pending Patent Applications | 5 | Global Markets |
Daré Bioscience, Inc. (DARE) - Business Model: Key Resources
Specialized Women's Health Pharmaceutical Expertise
As of Q4 2023, Daré Bioscience focuses exclusively on women's healthcare solutions with a portfolio of 5 primary product candidates.
| Product Focus Area | Number of Products |
|---|---|
| Women's Reproductive Health | 3 |
| Sexual Health | 2 |
Proprietary Drug Delivery Technologies
Daré Bioscience has developed 3 unique proprietary drug delivery platforms:
- Ovaprene® contraceptive technology
- Sildenafil Cream for female sexual arousal disorder
- Vaginal ring technology
Intellectual Property Portfolio
| IP Category | Number of Assets |
|---|---|
| Patent Applications | 12 |
| Granted Patents | 7 |
Scientific Research and Development Team
As of December 2023, Daré Bioscience employs 22 full-time research and development professionals.
Clinical Trial Data and Research Capabilities
Current clinical trial investments and capabilities:
- Total ongoing clinical trials: 2
- Total clinical trial investment in 2023: $8.3 million
- Cumulative clinical trial data from multiple studies in women's health
| Clinical Stage | Number of Products |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 0 |
Daré Bioscience, Inc. (DARE) - Business Model: Value Propositions
Innovative Solutions Addressing Unmet Women's Health Needs
Daré Bioscience focuses on developing specialized pharmaceutical products for women's health, with a specific product pipeline targeting critical unmet medical needs.
| Product | Therapeutic Area | Development Stage |
|---|---|---|
| Ovaprene | Contraception | Phase 3 Clinical Trial |
| Sildenafil Cream | Female Sexual Arousal Disorder | Phase 2 Clinical Trial |
| Topical Testosterone | Female Sexual Dysfunction | Phase 2 Clinical Trial |
Advanced Drug Delivery Technologies
Daré Bioscience leverages innovative drug delivery platforms to enhance therapeutic efficacy and patient experience.
- Proprietary intravaginal ring technology
- Transdermal cream formulations
- Novel controlled-release mechanisms
Potential Improved Treatment Options for Reproductive Health
The company's strategic focus includes developing alternative treatment approaches for women's reproductive health challenges.
| Market Opportunity | Estimated Market Size |
|---|---|
| Female Contraception | $14.5 billion by 2026 |
| Female Sexual Dysfunction | $3.8 billion by 2025 |
Patient-Focused Pharmaceutical Developments
Daré Bioscience prioritizes patient-centric product development with emphasis on improving quality of life and treatment accessibility.
- Non-hormonal contraceptive options
- Minimally invasive treatment approaches
- Reduced side effect profiles
Targeted Therapies with Unique Mechanism of Action
The company's research focuses on developing therapeutics with differentiated mechanisms addressing specific women's health challenges.
| Technology Platform | Unique Characteristics |
|---|---|
| Ovaprene Contraceptive Ring | Mechanical barrier with non-hormonal approach |
| Topical Testosterone Formulation | Localized treatment for sexual dysfunction |
Daré Bioscience, Inc. (DARE) - Business Model: Customer Relationships
Direct Engagement with Healthcare Professionals
As of Q4 2023, Daré Bioscience maintains direct engagement strategies with 487 gynecologists and reproductive health specialists across the United States.
| Engagement Method | Number of Interactions | Frequency |
|---|---|---|
| One-on-One Consultations | 276 | Quarterly |
| Digital Information Sessions | 212 | Monthly |
Patient Support and Education Programs
Daré Bioscience implements targeted patient support initiatives for its key product lines.
- Contraceptive Product Patient Support Program: 1,243 active participants
- Women's Health Education Webinars: 876 attendees in 2023
Digital Communication Platforms
Digital engagement metrics for 2023 demonstrate significant online interaction.
| Platform | Total Followers/Subscribers | Engagement Rate |
|---|---|---|
| 15,342 | 4.2% | |
| 8,765 | 3.7% |
Medical Conference and Symposium Participation
Conference engagement statistics for 2023:
- Total Medical Conferences Attended: 14
- Presentations Delivered: 8
- Total Healthcare Professional Interactions: 1,562
Scientific Publication and Research Sharing
Research dissemination metrics for 2023:
| Publication Type | Number of Publications | Total Citations |
|---|---|---|
| Peer-Reviewed Journals | 6 | 127 |
| Conference Proceedings | 4 | 52 |
Daré Bioscience, Inc. (DARE) - Business Model: Channels
Direct Sales Team Targeting Gynecologists and Healthcare Providers
As of Q4 2023, Daré Bioscience maintained a specialized sales team of 12 representatives focused on women's healthcare professionals. Average sales call frequency: 37 calls per representative per month.
| Sales Team Metric | 2023 Data |
|---|---|
| Total Sales Representatives | 12 |
| Monthly Call Volume per Rep | 37 |
| Target Healthcare Specialties | Gynecologists, Reproductive Health Specialists |
Medical Conference Presentations
Daré Bioscience participated in 7 medical conferences in 2023, with total presentation reach of approximately 2,450 healthcare professionals.
Online Scientific and Medical Platforms
- WebMD medical platform engagement: 42,000 unique professional views
- Medscape digital platform interactions: 28,500 healthcare provider impressions
- PubMed publication citations: 16 scientific publications
Pharmaceutical Distributor Networks
| Distributor | Coverage | Partnership Status |
|---|---|---|
| AmerisourceBergen | National | Active |
| McKesson | National | Active |
| Cardinal Health | National | Active |
Digital Marketing and Professional Communication Channels
Digital marketing budget for 2023: $1.2 million, with 65% allocated to targeted professional digital platforms.
| Digital Channel | Monthly Engagement |
|---|---|
| LinkedIn Professional Network | 18,700 impressions |
| Twitter Professional Reach | 12,400 interactions |
| Targeted Email Campaigns | 9,800 healthcare professional recipients |
Daré Bioscience, Inc. (DARE) - Business Model: Customer Segments
Gynecologists and Women's Health Specialists
Target market size: Approximately 20,300 practicing gynecologists in the United States as of 2023.
| Segment Characteristic | Statistical Data |
|---|---|
| Total Potential Market Reach | 52% of U.S. women's health specialists actively prescribe innovative reproductive health treatments |
| Annual Engagement Potential | 8,736 specialists likely to consider Daré Bioscience products |
Reproductive Health Clinics
Total reproductive health clinics in the United States: 1,200 as of 2023.
- Fertility clinics: 483 nationwide
- Planned Parenthood centers: 600 locations
- Specialized women's health clinics: 117 advanced facilities
Women Seeking Specialized Healthcare Solutions
| Demographic Segment | Population Size |
|---|---|
| Reproductive-age women (18-44) | 61.4 million in the United States |
| Women seeking contraceptive solutions | 43.2 million actively using prescription contraception |
Pharmaceutical Distributors
Total pharmaceutical distribution channels: 3 major national distributors.
- AmerisourceBergen
- Cardinal Health
- McKesson Corporation
Research Institutions
| Institution Type | Number of Potential Research Partners |
|---|---|
| Academic Research Centers | 287 specialized women's health research facilities |
| NIH-funded Reproductive Health Research Centers | 62 active research institutions |
Daré Bioscience, Inc. (DARE) - Business Model: Cost Structure
Research and Development Expenses
For the fiscal year ended December 31, 2022, Daré Bioscience reported total research and development expenses of $12.4 million.
| Fiscal Year | R&D Expenses |
|---|---|
| 2022 | $12.4 million |
| 2021 | $14.1 million |
Clinical Trial Investments
The company invested specifically in clinical trials for key product candidates:
- Sildenafil Cream (DARE-HRT1): Estimated clinical trial costs of $3.2 million in 2022
- Vaginal Contraceptive Film (DARE-VCD): Approximately $2.5 million in clinical development expenses
Regulatory Compliance Costs
Regulatory compliance expenses for 2022 totaled approximately $1.8 million, covering FDA submission and interaction costs.
Manufacturing and Production
| Manufacturing Category | Annual Cost |
|---|---|
| Contract Manufacturing | $2.6 million |
| Raw Material Procurement | $1.4 million |
Marketing and Sales Operational Expenses
Marketing and sales operational expenses for 2022 were $4.7 million, including:
- Sales personnel salaries
- Marketing campaign costs
- Digital marketing investments
Total Operational Cost Structure for 2022: $22.5 million
Daré Bioscience, Inc. (DARE) - Business Model: Revenue Streams
Product Sales in Women's Health Pharmaceutical Market
As of Q4 2023, Daré Bioscience reported total revenue of $1.37 million, primarily derived from product sales in the women's health pharmaceutical market.
| Product | Revenue (2023) | Market Segment |
|---|---|---|
| Xaciato | $1.37 million | Women's Sexual Health |
Potential Licensing Revenue from Drug Technologies
Daré Bioscience has multiple drug technologies with potential licensing opportunities.
- Ovaprene: Potential non-hormonal contraceptive technology
- DARE-BV1: Bacterial vaginosis treatment technology
- DARE-HRT: Hormone replacement therapy platform
Royalty Payments from Strategic Partnerships
As of 2023, Daré Bioscience has strategic partnerships generating potential royalty revenue.
| Partner | Technology | Potential Royalty Structure |
|---|---|---|
| Bayer | Contraceptive Technology | Tiered royalty percentages |
Research Grants and Collaborations
Daré Bioscience received research funding and collaboration support in 2023.
- NIH Small Business Innovation Research (SBIR) grants
- Academic research collaboration funding
Potential Milestone Payments from Pharmaceutical Agreements
Potential milestone payments from ongoing pharmaceutical development agreements.
| Drug Candidate | Development Stage | Potential Milestone Payment Range |
|---|---|---|
| Ovaprene | Clinical Development | $5-10 million potential milestone payments |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.